August 8, 2018
FLX Bio to Present at the 2018 Wedbush PacGrow Healthcare Conference Read more

June 1, 2018
FLX Bio To Present At The Jefferies Global Healthcare Conference Read more

April 12, 2018
FLX Bio to Highlight New Preclinical Data from CCR4 and USP7 Programs at the American Academy For Cancer Research (AACR) Annual Meeting Read more

April 1, 2018
Alexander Y. Rudensky, Ph.D., Chair of FLX Bio Scientific Advisory Board, Profiled in the Proceedings of the National Academies of Science Read more

February 12, 2018
FLX Bio to Present at RBC Capital Markets 2018 Global Healthcare Conference Read more

February 5, 2018
FLX Bio Adds Distinguished Biopharma Industry Leader Michael Giordano, M.D., to Board of Directors Read more

January 3, 2018
FLX Bio Appoints Dirk G. Brockstedt, Ph.D., as Senior Vice President of Biology Read more

December 21, 2017
FLX Bio Completes $60 Million Series C Financing Read more

November 27, 2017
FLX Bio to Present at Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference Read more

November 11, 2017
FLX Presents Poster at SITC 2017: Potent and Selective CCR4 Antagonists Inhibit Regulatory T Cell Recruitment, Increase Effector T Cell Numbers, and Potentiate Anti-Tumor Responses in Mice (PDF) Read more

November 10, 2017
FLX Presents Poster at SITC 2017: Patient Selection Strategies and Pharmacodynamic Assays for CCR4 Antagonists (PDF) Read more

September 21, 2017
FLX Bio Selects Immuno-Oncology Clinical Candidate Read more

August 10, 2017
Biocentury Innovations Profile: Flexing Against Suppression (PDF) Read more

May 31, 2017
FLX Bio Adds Distinguished Immuno-Oncology Experts to Its Scientific Advisory Board Read more

March 31, 2017
FLX Bio to Present Poster at the American Association of Cancer Research (AACR) Conference on its Lead Immuno-Oncology Program Targeting CCR4 Read more

December 12, 2016
FLX Bio Appoints Linda Kozick to Its Board of Directors Read more

December 1, 2016
FLX Bio Announces Poster Presentations at the American Society of Hematology Conference on FLX925, a Small Molecule FLT3/CDK4/6 Inhibitor Read more

November 29, 2016
Cofactor Genomics Partners with FLX Bio for Immuno-Oncology Analysis Platform Read more

April 26, 2016
FLX Bio Announces $50 Million Series B Financing Read more

April 5, 2016
FLX Bio Completes Leadership Team in Immuno-Oncology Drug Discovery Read more

February 8, 2016
FLX Bio Hires Senior Leaders in Immuno-Oncology Drug Discovery Read more

November 30, 2015
Bloomberg TV — Redefining Health Care: Recent Trends in Digital Biotech Read more

October 1, 2015
FLX Bio Takes Up Flexus Mantle, Marches on in Immuno-Oncology (PDF) Read more

August 31, 2015
FLX Bio Announces Initiation of Phase 1 Trial of FLX925 Read more

August 31, 2015
FLX Bio Announces Senior Management Hires Read more

February 23, 2015
Bristol-Myers Squibb To Expand Its Immuno-Oncology Pipeline with Agreement to Acquire Flexus Biosciences, Inc. Read more